Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canopus BioPharma has signed a licensing agreement with the Wisconsin Alumni Research Foundation, an organization serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to companies in Wisconsin, US and worldwide.
Subscribe to our email newsletter
The agreement provides comprehensive licensing rights and patent protection relating to Canopus’s Phase II oncology drug candidate, CB1400. Canopus BioPharma expects to develop CB1400 as a method for preventing and reducing mucositis.
Canopus BioPharma’s CB1400, a former anti-schistosomal drug, is currently in Phase II clinical development by Canopus as an anti-mucositis preventative agent in patients receiving radio or chemotherapy treatment.
Patrick Prendergast, chairman and CEO of Canopus, said: “Securing the rights to the Wisconsin Alumni Research Foundation (WARF) patents strengthens Canopus BioPharma’s intellectual property position for future licensing opportunities of CB1400, one of our most exciting products.”